BioCentury | Aug 8, 2019
Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

...royalties. The deal is subject to Aevi securing additional financing. Zenith, Newsoara in ZEN-3694 deal Zenith Epigenetics...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer

...tumors. AstraZeneca plc has AZD4573, a CDK9 inhibitor, in Phase I testing for hematologic malignancies. Zenith Epigenetics Corp....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital Zenith Epigenetics Corp....
...is booming, so it makes sense to combine the two,” said Sanjay Lakhotia, CBO of Zenith Epigenetics Corp....
...University, Shanghai, China Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), Waltham, Mass. Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. Zenith Epigenetics Corp....
BioCentury | Jul 31, 2017
Distillery Therapeutics

Cancer

...a small molecule BET bromodomain proteins inhibitor, in Phase I testing for unspecified cancer. Zenith Epigenetics Corp....
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...stable disease, while increases in those CTCs were associated with disease progression. LB-039 / 2 Zenith Epigenetics Corp....
BioCentury | Jun 27, 2016
Clinical News

ZEN-3694: Phase I started

...evaluate oral ZEN-3694 once daily in 28-day cycles with Xtandi enzalutamide in about 58 patients. Zenith Epigenetics Corp....
BioCentury | May 23, 2016
Financial News

Zenith Epigenetics completes venture financing

Zenith Epigenetics Corp. , Calgary, Alberta Business: Autoimmune, Cancer Date completed: 2016-05-16 Type: Venture financing Raised: $24.6 million Investor: Eastern Capital WIR Staff autoimmune cancer...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...Ltd. , Merck & Co. Inc. , Novartis AG , RaNa Therapeutics Inc., Sanofi and Zenith Epigenetics Corp....
...for specific bromodomains. McCaffrey is cofounder, president and CEO of Resverlogix Corp. and spinout company Zenith Epigenetics...
...Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Whitehead Institute for Biomedical Research , Cambridge, Mass. Zenith Epigenetics Corp....
BioCentury | Apr 17, 2014
Strategy

Expanding into new (bromo)domains

...to treat cancer and other diseases. Source: BCIQ: BioCentury Online Intelligence Company Product Description Status Zenith Epigenetics Corp....
BioCentury | Jan 9, 2014
Distillery Therapeutics

Indication: Various

...has completed two Phase IIb trials to treat cardiovascular disease. The company has spun out Zenith Epigenetics Corp....
Items per page:
1 - 10 of 14
BioCentury | Aug 8, 2019
Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

...royalties. The deal is subject to Aevi securing additional financing. Zenith, Newsoara in ZEN-3694 deal Zenith Epigenetics...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer

...tumors. AstraZeneca plc has AZD4573, a CDK9 inhibitor, in Phase I testing for hematologic malignancies. Zenith Epigenetics Corp....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital Zenith Epigenetics Corp....
...is booming, so it makes sense to combine the two,” said Sanjay Lakhotia, CBO of Zenith Epigenetics Corp....
...University, Shanghai, China Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), Waltham, Mass. Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. Zenith Epigenetics Corp....
BioCentury | Jul 31, 2017
Distillery Therapeutics

Cancer

...a small molecule BET bromodomain proteins inhibitor, in Phase I testing for unspecified cancer. Zenith Epigenetics Corp....
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...stable disease, while increases in those CTCs were associated with disease progression. LB-039 / 2 Zenith Epigenetics Corp....
BioCentury | Jun 27, 2016
Clinical News

ZEN-3694: Phase I started

...evaluate oral ZEN-3694 once daily in 28-day cycles with Xtandi enzalutamide in about 58 patients. Zenith Epigenetics Corp....
BioCentury | May 23, 2016
Financial News

Zenith Epigenetics completes venture financing

Zenith Epigenetics Corp. , Calgary, Alberta Business: Autoimmune, Cancer Date completed: 2016-05-16 Type: Venture financing Raised: $24.6 million Investor: Eastern Capital WIR Staff autoimmune cancer...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...Ltd. , Merck & Co. Inc. , Novartis AG , RaNa Therapeutics Inc., Sanofi and Zenith Epigenetics Corp....
...for specific bromodomains. McCaffrey is cofounder, president and CEO of Resverlogix Corp. and spinout company Zenith Epigenetics...
...Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Whitehead Institute for Biomedical Research , Cambridge, Mass. Zenith Epigenetics Corp....
BioCentury | Apr 17, 2014
Strategy

Expanding into new (bromo)domains

...to treat cancer and other diseases. Source: BCIQ: BioCentury Online Intelligence Company Product Description Status Zenith Epigenetics Corp....
BioCentury | Jan 9, 2014
Distillery Therapeutics

Indication: Various

...has completed two Phase IIb trials to treat cardiovascular disease. The company has spun out Zenith Epigenetics Corp....
Items per page:
1 - 10 of 14